

August 17, 2026

The Honorable Jerry Moran
Chairman
Senate Committee on Veterans' Affairs
412 Russell Senate Office Building
Washington, DC 20510

The Honorable Richard Blumenthal
Ranking Member
Senate Committee on Veterans' Affairs
412 Russell Senate Office Building
Washington, DC 20510

Dear Chairman Moran and Ranking Member Blumenthal:

On behalf of the undersigned organizations, representing patients, survivors, caregivers, clinicians, and researchers dedicated to the fight against prostate cancer, we write to express our strong support for S. 4993, the Precision Oncology Program for Cancer of the Prostate (POPCaP) Authorization Act, introduced by Chairman Moran. We are grateful for his leadership in bringing this legislation before the Committee and respectfully urge swift consideration and advancement of this important bill.

Prostate cancer is the most commonly diagnosed cancer among men in the VA health care system, and veterans face a disproportionate risk of the disease due to service-related exposures, including Agent Orange and burn pits. Veterans also present with more advanced disease and experience higher mortality than the general population. Precision oncology — including genetic and genomic testing to guide treatment — has transformed care for prostate cancer patients, yet access to these tools remains inconsistent across the VA system.

S. 4993 would authorize the successful Precision Oncology Program for Cancer of the Prostate, ensuring that Centers of Excellence continue to offer genetic sequencing on a uniform platform for veterans with advanced prostate cancer; coordinate care through a Telemedicine Tumor Board so that veterans anywhere in the country can benefit from specialized expertise; maintain a prostate cancer registry to track relevant genetic mutations; support biomarker-specific clinical trials and participation in industry-sponsored precision oncology studies; and provide travel support to help eligible veterans access these studies.

This legislation secures the vital POPCaP program, allowing it to continue to close gaps in cancer care for veterans, relying on precision oncology models and expanded access to clinical trials to improve outcomes. Passage of S. 4993 would ensure that veterans with prostate cancer, regardless of where they receive care, have access to the same cutting-edge, personalized treatment options as their civilian counterparts. We also note that a companion bill, H.R. 8553, was introduced in the House of Representatives by Representatives Greg Murphy, M.D. (R-NC) and Herb Conaway, M.D. (D-NJ), reflecting bipartisan, bicameral support for this effort.

We thank Chairman Moran for his leadership on this issue and thank the Committee for its continued commitment to improving cancer care for our nation's veterans. We urge you to support swift consideration and passage of S. 4993, and we stand ready to serve as a resource to the Committee as it considers this legislation.

Sincerely,

American Association of Clinical Urology (AACU)
American Cancer Society Cancer Action Network
American Urological Association (AUA)

Fans for the Cure
FORCE: Facing Our Risk of Cancer Empowered
ICAN, International Cancer Advocacy Network
LUGPA
Men's Health Network
National Alliance of State Prostate Cancer Coalitions
National Patient Advocate Foundation
Prevent Cancer Foundation
Prostate Cancer Education Council
Prostate Cancer Foundation
The Prostate Cancer Clinical Trials Consortium
Triage Cancer
Veterans Prostate Cancer Awareness Inc.
Vietnam Veterans of America
Wounded Warrior Project
Your Prostate Cancer.help, Inc
ZERO Prostate Cancer